文献速递淋巴瘤

慢性淋巴细胞白血病中的染色体复杂核型:定义、关联与临床影响

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
PubMed 文献 · Blood · 2019-01-02

该回顾性研究纳入5290例有染色体显带分析(CBA)数据的慢性淋巴细胞白血病(CLL)患者,探讨复杂核型(CK)的临床生物学关联与预后影响。研究发现≥5个异常的髙复杂核型(high-CK)患者预后均差,独立于临床分期、TP53异常及免疫球蛋白重链可变基因突变状态;而CK伴+12、+19者病程异常惰性。作者提出基于CK、TP53异常和IGHV突变状态的新型分层模型,并指出将high-CK纳入风险分层前需前瞻性临床验证。

要点

  • 髙复杂核型(≥5个染色体异常)患者预后均差,独立于临床分期、TP53异常和IGHV突变状态。
  • 低复杂核型(3个异常)和中复杂核型(4个异常)仅在伴TP53异常时才表现为侵袭性病程。
  • 复杂核型伴+12、+19的患者呈现异常惰性的临床特征。

核心结论

  • 复杂核型不应被公认为CLL的不良因素,其代表一组临床行为异质性的群体。
  • 髙复杂核型(≥5个染色体异常)为预后不良因素,独立于其他生物标志物。
  • 在最终将髙复杂核型纳入CLL风险分层前,需前瞻性临床验证。

研究设计与样本

  • 回顾性研究,纳入5290例有染色体显带分析(CBA)数据的CLL患者。
  • 复杂核型定义为CBA检出≥3个染色体异常(结构和/或数目异常)。
  • 髙复杂核型定义为≥5个异常,低复杂核型为3个异常,中复杂核型为4个异常。

主要发现

  • 髙复杂核型(≥5个异常)患者临床结局均差,独立于临床分期、TP53异常(17p缺失和/或TP53突变)及IGHV突变状态。
  • 低复杂核型(3个异常)和中复杂核型(4个异常)患者仅在伴TP53异常时才表现为侵袭性病程。
  • 复杂核型伴+12、+19的患者呈现异常惰性的临床特征。
  • 基于CK、TP53异常和IGHV突变状态提出的分层模型中,髙复杂核型患者预后最差,而缺乏CK或TP53异常的突变型CLL以及CK伴+12、+19者总生存最长。

临床怎么用

  • 作者提出基于CK、TP53异常和IGHV突变状态的新型分层模型,其中髙复杂核型患者预后最差。
  • 作者指出在最终将髙复杂核型纳入CLL风险分层前需前瞻性临床验证。

局限性

  • 原文为回顾性研究。
  • 原文指出在最终将髙复杂核型纳入CLL风险分层前需前瞻性临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with ≥5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and +12,+19 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hypermutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with +12,+19, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with ≥5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019. PMID: 30602617. doi:10.1182/blood-2018-09-873083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。